B3GAT2

Across TCGA pan-cancer cohorts, B3GAT2 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated B3GAT2 data layer compared with 23 for mass-spec protein.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where higher B3GAT2 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated B3GAT2 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

KIRC, ESCA, and BLCA are the cancer types where B3GAT2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KIRC	DFS	Median	All	0.133	0.796	<.001	36	view →
ESCA	DFS	Median	II,III,IV	0.151	0.529	<.001	18	view →
BLCA	OS	Median	IV	0.153	0.599	.018	9	view →
UCEC	DFS	Median	All	1.000	0.629	.023	8	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

B3GAT2–KIRC (DFS)

Open the KIRC breakdown →